Cantor Fitzgerald set a $17.00 target price on Horizon Pharma (NASDAQ:HZNP) in a report published on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts also recently issued reports on HZNP. ValuEngine downgraded shares of Horizon Pharma from a buy rating to a hold rating in a report on Sunday, December 31st. Jefferies Group reissued a buy rating and issued a $16.00 price target on shares of Horizon Pharma in a research note on Wednesday, September 27th. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma and gave the stock a buy rating in a research note on Sunday, October 15th. Cowen reissued a buy rating on shares of Horizon Pharma in a research note on Thursday, September 28th. Finally, Goldman Sachs Group initiated coverage on shares of Horizon Pharma in a research note on Thursday, September 28th. They issued a buy rating and a $16.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. Horizon Pharma currently has an average rating of Buy and a consensus price target of $18.75.
Horizon Pharma (HZNP) traded down $0.22 during midday trading on Monday, hitting $15.16. 1,510,200 shares of the stock were exchanged, compared to its average volume of 1,543,443. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $18.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. The company has a market cap of $2,510.00, a P/E ratio of -4.99, a P/E/G ratio of 0.73 and a beta of 1.30.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same period in the previous year, the firm posted $0.70 EPS. The firm’s revenue was up 30.1% compared to the same quarter last year. sell-side analysts predict that Horizon Pharma will post 0.72 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Horizon Pharma by 1.8% in the second quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after purchasing an additional 239,014 shares during the period. Vanguard Group Inc. grew its holdings in Horizon Pharma by 1.8% in the second quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after purchasing an additional 233,443 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Horizon Pharma by 18.6% in the third quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock worth $94,254,000 after buying an additional 1,167,722 shares in the last quarter. Paulson & CO. Inc. bought a new position in shares of Horizon Pharma in the second quarter worth approximately $58,584,000. Finally, State Street Corp lifted its stake in shares of Horizon Pharma by 12.0% in the second quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after buying an additional 524,187 shares in the last quarter. Institutional investors own 86.58% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Analysts Give Horizon Pharma (HZNP) a $17.00 Price Target” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/cantor-fitzgerald-analysts-give-horizon-pharma-hznp-a-17-00-price-target.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.